Ypsomed has achieved an important regulatory milestone in China: the packaging registration for the YpsoMate 1 mL has been officially approved. This approval authorizes Ypsomed to commence full-scale production of the YpsoMate 1 mL in strict accordance with the registered documentation, paving the way for commercial supply to customers.
First product registered at Ypsomed Changzhou
This achievement marks the first product from Ypsomed’s Changzhou site to receive official registration approval – a key milestone in the facility’s continued development and integration into Ypsomed’s global manufacturing network. With this registration in place, the Changzhou team can now prepare to supply Chinese customers. The approval enables Ypsomed’s pharmaceutical partners to proceed with their joint approval procedures for the associated drug-device combinations.
Strengthening our global footprint
The successful registration of the YpsoMate mL in China strengthens Ypsomed’s regional presence, and reinforces its commitment to building a resilient, globally distributed production network that ensures reliable access to innovative self-injection devices of the highest quality.
